脑膜瘤:国际脑膜瘤联盟共识综述——面向临床医生、研究人员和患者的科学进展与治疗范式
脑膜瘤是成人最常见的原发性颅内肿瘤,发病率因人口老龄化和神经影像可及性增加而上升。国际脑膜瘤联盟专家针对分子分类、生物标志物、治疗策略、全身治疗试验、健康相关生活质量及特殊人群管理等方面存在的差距,撰写了本共识叙述性综述,讨论当前知识状态与持续挑战以规划未来研究方向。
要点
- 脑膜瘤是成人最常见的原发性颅内肿瘤,发病率因人口老龄化和神经影像可及性增加而上升。
- 部分脑膜瘤生物学上具有侵袭性,与治疗抵抗相关,导致显著神经病学并发症甚至死亡。
- 脑膜瘤统一的分子分类尚未建立,仍是cIMPACT-NOW工作组的总体目标。
核心结论
- 脑膜瘤生物学理解已有实质性进展,分子生物标志物已被纳入分级和预后评估。
- 脑膜瘤统一的分子分类尚未建立,仍是cIMPACT-NOW工作组的总体目标。
- 特定脑膜瘤病例和患者群体如何优化管理仍存在临床均衡。
研究设计与样本
- 国际脑膜瘤联盟成员包括领域领先专家 prepared 本综合共识叙述性综述,面向临床医生、研究人员和患者。
主要发现
- 脑膜瘤是成人最常见的原发性颅内肿瘤,发病率因人口老龄化和神经影像可及性增加而上升。
- 大多数脑膜瘤表现为非恶性行为,但一部分生物学上具有侵袭性,与治疗抵抗相关,导致显著神经病学并发症甚至死亡。
- 近年来对脑膜瘤生物学的理解取得有意义进展,促使分子生物标志物被纳入分级和预后评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.
引用
- Wang JZ, Landry AP, Raleigh DR, et al. Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neuro Oncol. 2024. PMID: 38695575. doi:10.1093/neuonc/noae082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。